Rules/misleading presentation/US-MIS-016

Statistical significance should not be used to imply unproven clinical significance

AI-verifiedwarningBinding lawRaised as a question — a person decides

Rule

An ad may be misleading if it invokes 'statistical significance' to support a claim whose clinical significance or validity has not been demonstrated.

Check

For claims citing statistical significance, check whether clinical significance is separately demonstrated.

Escalate when

Whether clinical significance has been adequately demonstrated is a scientific judgment call.

Where this comes from

21 CFR 202.1(e)(7)(ii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…ct. (7) Advertisements that may be false, lacking in fair balance, or otherwise misleading. An advertisement may be false, lacking in fair balance, or otherwise misleading or otherwise violative of section 502(n) of the act if it: (i) Contains favorable information or conclusions from a study that is inadequate in design, scope, or conduct to furnish significant support for such information or conclusions. (ii) Uses the concept of “statistical significance” to support a claim that has not been demonstrated to have clinical significance or validity, or fails to reveal the range of variations around the quoted average results. (iii) Uses statistical analyses and techniques on a retrospective basis to discover and cite findings not soundly supported by the study, or to suggest scientific validity and rigor for data from studies the design or protocol of which are not amenable to formal statistical evaluations. (iv) Uses tables or graphs to distort or misrepres…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is verbatim from the operative regulatory text at (e)(7)(ii), not from an example, definition, or preamble; it is one of the enumerated bases on which 'An advertisement may be false, lacking in fair balance, or otherwise misleading.' The rule statement follows directly.
- Not overstated: the rule says 'may be misleading', mirroring the regulation's permissive 'may be false, lacking in fair balance, or otherwise misleading' framing of paragraph (e)(7), rather than converting it into a flat prohibition. Severity 'warning' is consistent with that softer framing (contrast the mandatory (e)(6) list).
- Atomic: (e)(7)(ii) contains two independent prongs — misuse of 'statistical significance' and failure to reveal the range of variations around quoted averages. The rule isolates the first prong only, and the quote is truncated accordingly, so no bundling.
- Determinism 'judgment' is correct: whether clinical significance or validity 'has been demonstrated' turns on scientific adequacy of the evidence, not presence/absence of a literal string. The escalation note states this accurately.
- Authority 'binding' is correct — 21 CFR 202.1 is a codified regulation, and the excerpt confirms its enforcement hook via section 502(n) misbranding.
- Locator 21 CFR 202.1(e)(7)(ii) matches the quoted subparagraph exactly.
- applies_when 'promotional' is justified: 202.1 governs prescription-drug advertisements, and (l)(2) extends comparable treatment to promotional labeling pieces. Minor unflagged nuance: the source is specific to prescription drugs, so the rule is nominally slightly broader in product scope, and the check drops the 'or validity' limb present in the rule statement — neither is significant enough to withhold a pass.

Nearby rules

US-MIS-017